Skip to content
Business

J&J’s new esketamine drug for depression, Spravato, not worth the money or the risk, watchdog says

The nasal spray for treatment-resistant depression was called overpriced. ICER also found an absence of long-term safety data.

Spravato, Johnson & Johnson's brand name for esketamine, was approved by the FDA in March 2019 for treatment-resistant depression.
Spravato, Johnson & Johnson's brand name for esketamine, was approved by the FDA in March 2019 for treatment-resistant depression.Read moreJanssen Pharmaceutica / Janssen Pharmaceutica
    by Sam Wood
    Published